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Skeletal muscle injuries are the most common sports-related injuries and present a challenge in primary care and sports medicine.
Most types of muscle injuries would follow three stages: the acute inflammatory and degenerative phase, the repair phase
and the remodeling phase. Present conservative treatment includes RICE (rest, ice, compression, elevation), nonsteroidal anti-
inflammatory drugs (NSAIDs) and physical therapy. However, if use improper, NSAIDs may suppress an essential inflammatory
phase in the healing of injured skeletal muscle. Furthermore, it remains controversial whether or not they have adverse eﬀects on
the healing process or on the tensile strength. However, several growth factors might promote the regeneration of injured skeletal
muscle, many novel treatments have involved on enhancing complete functional recovery. Exogenous growth factors have been
shown to regulate satellite cell proliferation, diﬀerentiation and fusion inmyotubes in vivo and in vitro, TGF-β1 antagonists behave
as inhibitors of TGF-β1. They prevent collagen deposition and block formation of muscle fibrosis, so that a complete functional
recovery can be achieved.
1. Introduction
Skeletal muscle injuries are the most common sports-related
injuries and present a challenge in primary care and sports
medicine. Athletes sustain muscle injuries through a variety
of mechanisms, including direct trauma (e.g., lacerations,
strains, and contusions) and indirect injuries (related to
ischemia and neurological dysfunctions).
A regeneration process that is similar in most types
of muscle injuries, has been observed. However, complete
recovery from the injury is compromised due to the devel-
opment of fibrosis in the second week after the injury. The
formed scar tissue always is mechanically inferior and there-
fore much less able to perform the functions of a normal
muscle fiber. It is also more susceptible to reinjury [1, 2]. To
minimize the disability and enhance full functional recov-
ery after skeletal muscle injuries, the current conservative
treatment includes limiting the bleeding with compression,
elevation, and local cooling, nonsteroidal anti-inflammatory
drugs (NSAIDs), and physical therapy [3].
Recently, it has been suggested that growth factors might
promote the regeneration of injured skeletal muscle, and
many novel treatments have been developed.
This review paper focuses on therapeutic approaches in-
cluding new knowledge of routine NSAIDs, novel biological
repair, and physical therapy. A search of the literature on the
treatment of skeletal muscle injuries was conducted using
PubMed and Medscape.
2. The Pathological Process
FollowingMuscle Injury
The general injury and repair mechanism is similar in most
types of muscle injuries. Three stages are distinguished: the
destruction and inflammatory phase (1 to 3 days), the repair
phase (3 to 4 weeks), and the remodeling phase (3 to 6
months) [4, 5]. The last two phases tend to overlap.
When a muscle is injured, the myofibers rupture and
necrotize. A haematoma is formed. At the same time during
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this first phase, the inflammatory cells can freely invade the
injury site because the blood vessels are torn. The most
abundant inflammatory cells are the polymorphonuclear
leukocytes. These are replaced by monocytes, a few hours
after the injury. These cells eventually transform into
macrophages. Macrophages have 2 functions. Firstly, they
remove the necrotic myofibers by phagocytosis. Secondly,
they produce, together with fibroblasts, chemotactic signals
such as growth factors, cytokines, and chemokines. The
extracellular matrix (ECM) also contains growth factors
that become active when tissue is damaged. Some of these
growth factors, such as FGF (fibroblast growth factor),
IGF-1 (insulin-like growth factor-1), IGF-2 (insulin-like
growth factor-2), TGF-β (transforming growth factor-β),
HGF (hepatocyte growth factor), TNF-α (tumor necrosis
factor-α), and IL-6 (interleukin-6) can activate myogenic
precursors, called the satellite cell [3, 6, 7].
The next phase, the repair phase, consists of 2 concomi-
tant processes. The first is the regeneration of the disrupted
myofibers. Regeneration can occur because there still is a
pool of undiﬀerentiated reserve cells, also called myogenic
precursors or satellite cells under the basal lamina of the
myofiber. The satellite cells will proliferate and eventually
diﬀerentiate into myoblasts. Because these new myoblasts
fuse with the injured myofibers, the gap formed between
the two ends of the injured myofiber is refilled. The second
process of the repair phase is the formation of a connective
tissue scar by fibrin and fibronectin, derived from blood
of the haematoma that was formed immediately after the
injury. The scar tissue gives the muscle strength to withstand
contractions, and it gives the fibroblasts an anchoring site to
invade the granulation tissue. However, in case of excessive
proliferation of these fibroblasts, dense scar tissue is formed
within the injured muscle. This not only interferes with the
repair process but also interrupts the muscle regenerative
process and contributes to incomplete functional recovery of
the injured muscle during the third phase, the remodeling
phase. In this last phase, the newly formedmyofibers mature.
At the same time, the scar tissue is reorganized and it
contracts [3, 6, 7].
Due to an injury, the intramuscular nerve branches can
be damaged. Hence, the muscle fibers may be denervated,
which might aﬀect the healing process negatively [8].
The whole process is coordinated through diﬀerent
mechanisms like cell-cell and cell-matrix interactions as well
as extracellular secreted factors. HGF, IL-1, and IL-6 are
secreted factors that can stimulate the activity of satellite
cells. FGF and IGF can also activate satellite cells, but in
contrast to IGF, FGF can also inhibit their diﬀerentiation,
while IGF stimulates the diﬀerentiation. TGF-β1 stimulates
collagen deposition, leading to the formation of fibrotic scar
tissue [9–13].
3. Therapeutic Strategies
A variety of conservative treatment strategies exist for acute
and chronic skeletal muscle injuries [14, 15]. The primary
treatment goals are to minimize further damage, relieve pain
and spasm, reduce haemorrhage and edema, and promote
healing. Furthermore, the recurrent nature of muscle injuries
often requires a functional approach from the acute phase to
the final goal of return to sports.
4. RICE
The best known treatment immediately after a muscle injury
is the “RICE approach”. This acronym stands for rest, ice,
compression and elevation. The aim is to minimize the
haematoma of the injured muscle and, subsequently, the
size of the connective tissue scar. However, the eﬀectiveness
of this approach has not been proven in any randomized
clinical trial [3]. Ice should be applied intermittently for 15
to 20 minutes with an interval of 30 to 60 minutes. Longer
periods of cold application lead to increased circulation and
increased bleeding [8].
5. Physiotherapy
Early mobilization accelerates capillary ingrowth and pro-
motes the regeneration of muscle fibers. The healed muscle
also more rapidly regains its preinjury level of strength.
However, early mobilization also has disadvantages. The
scar that is formed will be larger, and reruptures will be
more common. Therefore, rest is advised during the first 3
to 7 days to allow the scar tissue to gain strength. Subse-
quently, mobilization within the painfree limits is initiated.
Continued inactivity can lead to atrophy of the healthy
muscles, excessive deposition of connective tissue within the
muscles and a substantially retarded recovery of the strength
of the injured skeletal muscle. Exercises should be started
gradually. Isometric training should be followed by isotonic
training and isotonic training by isokinetic training once the
respective exercises can be performed without pain [3].
6. NSAIDs
NSAIDs are primarily used for their analgesic, anti-inflam-
matory, and antipyretic properties [16]. Inflammatory cells
play an important role in the healing process of an injured
muscle. Therefore, the use of drugs that inhibit these cells,
such as NSAIDs, is questioned nowadays. Experimental
studies in which NSAIDs were given immediately after the
injury, have shown conflicting results. NSAIDs would not
have a greater eﬀect on the pain of a muscle injury than
paracetamol, but they have more side eﬀects including
asthma exacerbations, gastrointestinal and renal side eﬀects,
hypertension, and other. However, NSAIDs also have bene-
ficial eﬀects. The inflammatory process can be excessive and
cause edema, resulting in anoxia and further cell death. This
can be prevented by the administration of low-dose NSAIDs
[17].
Rahusen et al. reviewed earlier reports on the use of
NSAIDs to clarify recommendations for their use [18]. Basi-
cally, NSAIDs should be given no sooner than 48 hours
following exercise-induced muscle injuries to provide anal-
gesia and to reduce the early inflammatory response. Earlier
use can interfere with the cell chemotaxis that is necessary
for the repair and remodeling of regenerating muscle.
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In the 2 days after the injury, paracetamol can be used
for analgesia. Prolonged use of NSAIDs (over 7 days) is
not recommended as it would delay muscle regeneration by
inactivating the proliferation and diﬀerentiation of satellite
cells and inhibiting the production of growth factors [18, 19].
It would also reduce the biomechanical strength of the
injured muscle and delay elimination of the haematoma and
the necrotic tissue [20]. In contrast with the findings of
these authors, Engelberg et al. and Almekinders [21] showed
no significant eﬀect on tensile strength recovery following
NSAID treatment for muscle strain injury. Engelberg et al.
further demonstrated that muscle strength also remained
unaltered [22].
7. Biological Repair
Recently, several studies have led to the identification of
growth factors that have the potential to influence the regen-
eration of injured muscles. Since then, multiple research
groups have been trying to find drugs that work on this
natural basis and can help an injuredmuscle to recover better
and/or faster [12, 23, 24] (Figure 1). To achieve this goal,
the researchers investigated several biological growth factors,
such as exogenous growth factors which would promote
healing of injured muscle fibers, and TGF-β1, the inhibition
of which would block the muscle fibrosis (Table 1).
Several growth factors are capable of promoting muscle
regeneration [13, 25]. These include basic fibroblast growth
factor (bFGF), insulin growth factor (IGF), nerve growth
factor (NGF), TGF-β1, and platelet-derived growth factor
(PDGF). Mitchell et al. reported that the short biologic half-
life of administered bFGF may limit its stimulatory eﬀect on
satellite cells [26]. They coinjected bFGF with heparin and
used sustained release polymers without success. Conversely,
Armand et al. found that the direct delivery of recombinant
bFGF-6 into the site of injury can accelerate the regeneration
of the soleus muscle in adult mice by stimulating the
diﬀerentiation process of the myotubes [27].
Takahashi et al. observed that gene delivery of IGF-1 via
electroporation resulted in an increased number of regener-
ating myofibers by 2 weeks after injury and in an increased
regenerating myofiber size by 4 weeks after injury [28].
Huard et al. injected IGF in healthy old men, thus preventing
the loss of muscle mass that is typical of aging. However,
IGF-injection has side eﬀects in that it promotes the
development of fibrosis by stimulating the production of
matrix components such as collagen and decreasing the
expression of matrix-degrading enzymes such as collagenase
[29]. In a mice model of muscle strain, Kasemkijwattana
et al. evaluated the ability of bFGF, NGF and IGF-1 to
promote muscle regeneration in vivo by three repeated
injections of 100 ng into the injury site 1, 3, and 5 days after
the injury [30]. In this study, physiologic strength testing
was correlated with histologic analysis of the treated and
nontreated muscles; the number and diameter of regen-
erating myofibers were monitored as an index of muscle
regeneration. Their data indicated that bFGF and IGF-1,
properly applied, can improve muscle performance after a
strain injury. Throughout this study, growth factors had been
injected on only 1 to 3 and 5 days after injury, resulting
in an improvement of the tetanic and fast-twitch strength
of the treated muscle, when compared with sham-injected
strain-injured muscle. In addition, NGF was found capable
of enhancing fast-twitch strength, but the titanic strength was
not significantly diﬀerent between the treated and nontreated
muscle [30].
Miller et al. postulated that local delivery of HGF would
augment satellite cell activation in regenerating muscle, and
that this increased number of myogenic precursor cells
would lead to an enhancement of muscle repair. Their study
showed that, when HGF was injected in injured muscles,
the number of myoblasts increased, but this increase did not
lead to a better regeneration of the injected muscle. Instead,
when HGF was injected the first 4 days after injury, muscle
regeneration was inhibited. When it was administered later,
the injection had no eﬀect. Miller et al. also found that HGF
had a dose-dependent eﬀect on the number of myoblasts
in regenerating muscles [31]. Two diﬀerent doses of HGF,
6.25 and 50 ng, were used in this study. Treatment with
6.25 ng HGF did not significantly increase the number of
myoblasts compared with control at any time tested. In
contrast, muscles treated with 50 ngHGF on the day of injury
and analyzed 1 day later yielded about threefoldmoreMyoD-
positive cells than did control muscles. In muscles further
treated with HGF on subsequent days and analyzed either
2 or 3 days after injury, no significantly increased number
of myoblasts was observed. This study demonstrated the
eﬀects of exogenous HGF administration on satellite cell
activation and diﬀerentiation in regenerating mouse muscles
after trauma. It showed the dual role HGF plays in regulating
satellite cell activation and diﬀerentiation [31].
Kasemkijwattana and Menetrey et al. observed that b-
FGF, IGF-1, and NGF are potent stimulators of the prolif-
eration and fusion of myoblasts in vivo [1, 30, 32]. These
growth factors were injected into mice with lacerations of the
gastrocnemius muscle. Muscle regeneration was evaluated at
1 week by histological staining and quantitative histology.
Muscle healing was assessed histologically and the contractile
properties were measured 1 month after injury. In the
treated group, the number of regenerating myofibers was
increased 3.5 times for bGF and IGF-1 and 1.5 times for NGF.
Those data suggested that specific growth factors were able
to improve regeneration of injured muscle by stimulating
myogenic proliferation and diﬀerentiation.
As discussed above, regeneration of an injured muscle
consists of 2 elements. First, there needs to be proliferation
and diﬀerentiation of myoblasts. This is promoted by growth
factors (Table 1). Secondly, scar tissue has to be minimal.
Many studies indicate that the overproduction of TGF-β1
is responsible for the tissue fibrosis both in animals and
humans [33]. Therefore, researchers have also tried to
develop drugs that inhibit TGF-β1. Chan et al. used the TFG-
β1 antagonist suramin in their study. Suramin is an antipar-
asitic and antitumor drug that competitively binds to the
TGF-β1 receptor. When suramin was injected immediately
or 7 days after the injury, it had only a minor eﬀect onmuscle
fibrosis. However, when a high dose of suramin was injected
14 days after injury, it prevented fibrosis more eﬀectively than
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Figure 1: Autologous platelet tissue graft: mechanism of action.
did a lower concentration or no suramin. There were more
regenerating myofibers in all the suramin-treated groups
than in the control groups. Just as the prevention of fibrosis,
the number of regenerating myofibers was dose dependent.
Side eﬀects of suramin are adrenocortical insuﬃciency,
malaise, neuropathy, and corneal deposits. Occasionally,
neutropenia, thrombocytopenia, and renal failuremay occur.
However, the toxicity of suramin delivered via intramuscular
injection has not yet been determined. In the study, no side
eﬀects were encountered [33]. These results are consistent
with those of Nozaki et al. who injected 2.5mg of suramin
2 weeks after contusion. They also found less fibrosis and
better healing of themuscle. Once healed, the injectedmuscle
was also stronger than the control muscles. A dose-response
eﬀect was not observed [34].
Decorin also inactivates the eﬀect of TGF-β1. Fukushima
et al. found that the injection of decorin at 10 and 15 days
after injury significantly decreased the amount of fibrosis.
Decorin had the additional advantage of enhancing the
regeneration of the injured muscle. There seemed to be a
dose-response eﬀect. No side eﬀects were observed [6].
8. Operative Treatment
Menetrey et al. used a muscle laceration model developed in
mice to investigate whether surgery is a better technique to
accelerate recovery of a muscle injury than immobilization.
At 2 days after the laceration, the mice that had surgery
only had a superficially located minor haematoma, while
the immobilized mice had a larger and deeper haematoma.
At the end, the immobilized mice had more and deeper
scar tissue than the sutured mice. The functional results
of surgery were also superior to those of immobilization
[35].
Surgery can only be implemented in specific conditions.
These include a large intramuscular haematoma, a complete
strain or tear of a muscle with few or no agonist muscles or
a partial strain if more than half of the muscle belly is torn
and if the patient complains of persistent (>4–6 months)
extension pain. After surgery, the operated limb should be
placed in a cast and immobilized in a neutral position with
an orthosis.
Table 1: Eﬀect of growth factors in musculoskeletal tissues.
Growth
factor
Skeletal
muscle
Hyaline
cartilage
Meniscus Ligament Bone
IGF-1 + + ± ± +
bFGF + + + ± +
NGF + − −
PDGF − − ±
EGF − + + +
TGF-alpha − + −
TGF-beta ± + ± ± +
BMP-2 + + +
+
Positive eﬀect; −no or negative eﬀect; blank: not tested; IGF-1: insulin-like
growth factor-1; bFGF: basic fibroblast growth factor; NGF: nerve growth
factor; PDGF: platelet-derived growth factor; EGF: epidermal growth factor;
TGF: transforming growth factor; BMP-2: bone morphogenetic protein-2.
9. Discussion
When a skeletal muscle is injured, satellite cells are activated
by a variety of growth factors within 18 hours of injury, as a
result of a response to a chemical stimulus [5, 36, 37]. At the
same time, inflammatory cells migrate to the injury site from
healthy areas of the muscle. Regeneration of single muscle
fibers or entire muscles can only occur when satellite cells
are activated. The optimal treatment for thesemuscle injuries
remains obscure in routine clinical practice.
The RICE approach is generally used in the acute stage.
The value of this treatment is not fully known, but most
authors consider it as not harmful and maybe helpful to
limit the bleeding in the muscles. It consists of rest, ice,
compression, and elevation [3]. During the first 7 days after
a muscle injury, rest should be taken, so that the scar tissue
can gain strength. Afterwards, physiotherapy can be started
[3].
Whether or not NSAIDs should be used in the treatment
of muscle injuries is still controversial. They have long
been the first choice to relieve pain after a skeletal muscle
injury. NSAIDsmay suppress the inflammatory response and
thus reduce the pain and swelling. However, this response
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is an essential phase in the healing of injured skeletal
muscle. Attempts to inhibit this phase will lead to an
incomplete functional recovery. NSAIDs could interfere with
macrophage action, limit phagocytic function, and impede
production of growth-promoting factors that are responsible
for regeneration after muscle injury. Experimental investi-
gations showed that NSAIDs might also decrease the tensile
strength of the injured muscle. Delayed muscle regeneration
has been observed in treated animals [38]. Other studies
did not come to this conclusion. Therefore, the exact role
of NSAIDs should be established in animal models and in
controlled clinical studies of skeletal muscle injuries. Until
then, most authors advise that NSAIDs should not be given
the first 48 hours after the injury. If the patient is in pain,
paracetamol can be administered for analgesia.
A better understanding of the biological and pathological
processes of muscle repair following skeletal muscle injury
has led to the use of growth factors.
Growth factors have been shown to regulate satellite cell
proliferation, diﬀerentiation, and fusion in myotubes in vivo
and in vitro. Recently, growth factors have been found to
promote the diﬀerentiation of myogenic cells in vivo and in
vitro and eventually enhance complete functional recovery
after muscle injury. Among these growth factors, NGF was
the first to be identified and used to promote repair in
peripheral and central nervous system injuries [39]. NGF
may also be useful in muscle regeneration, especially during
the reinnervation phase [40]. Injection of IGF increases the
number and the size of regenerating myofibers after muscle
injury [41]. Injection of b-FGF showed that this growth
factor is a potent stimulator of the proliferation and fusion
of myoblasts in vivo and in vitro [42].
TGF-β1 is a key factor, responsible for the formation
of muscle fibrosis during the repair process by stimulating
a variety of cells to increase the synthesis of numerous
matrix proteins [43]. In response to muscle injury, TGF-β1
provides an upregulated immune mechanism which leads to
an increased cellular adhesion to the ECM and ultimately
enhances myofibroblast survival by inhibiting apoptosis.
TGF-β1 is expressed at high levels and is associated with
massive muscle fibrosis observed in patients with Duchenne
muscular dystrophy. Based on this biological rationale of the
role of TGF-β1, several novel researches have focused on the
inhibition of TGF-β1 in muscle healing.
TGF-β1 antagonists behave as inhibitors of TGF-β1 by
binding to its receptor and blocking its actions, in order
to prevent collagen deposition and to block formation of
muscle fibrosis. Among these antifibrotic agents, decorin
and suramin have been demonstrated to block fibrosis and
promote functional recovery of injured skeletal muscle.
Decorin binds to TGF-β1 in order to counteract its action
and suramin competitively binds to the TGF-β1 receptor that
inhibits TGF-β expression [44]. However, the side eﬀects of
growth hormone factors must be taken into account, edema,
and arthralgia or myalgia being most common in adults [45].
Surgery should be preserved for special cases as men-
tioned before. If symptoms fail to improve, the possibility
of intramuscular haematoma and tissue damage should
be reconsidered. Measurement of intramuscular pressure,
soft-tissue X-rays, or ultrasound examination may be re-
quired [8].
Authors’ Recommendations
After a muscle injury, the RICE principle should be imple-
mented immediately. Seven days of rest are advised, after
which physiotherapy should be started. NSAIDs can be used
after 48 hours. The rationale for using NSAIDs in these
conditions is based on their anti-inflammatory properties.
Inflammation is an essential component of the healing pro-
cess. Therefore, the appropriate timing of NSAID adminis-
tration may play a key role in the therapeutic approach to
skeletal muscle injuries [46]. In the future, the routine use
of NSAIDs in muscle injuries should be further critically
evaluated and compared with other treatment strategies in
prospective randomized controlled trials.
The use of growth factors, particularly bFGF, NGF, and
IGF-1, is a novel therapeutic approach to promote full
functional recovery after muscle injuries. Autologous growth
factors might induce myogenic proliferation, stimulate dif-
ferentiation, and as such accelerate the healing of inflamed
and injured muscle. Inhibition of TGF-β1 expression con-
tributes to the blocking of muscle fibrosis in order to
minimize the formation of fibrous scar tissue and to promote
the restoration of functional muscle fibers within the injured
site.
A treatment that enhances the repair of injured muscle
could have significant clinical applications [47]. Therefore,
further studies must be conducted to evaluate the safety of
using growth factors and antifibrotic agents. Future research
should focus on the use of growth factors that facilitate
muscle regeneration in vivo. The balance between growth
and diﬀerentiation must be maintained in order to restore
functional muscle structure and to identify the diﬀerent roles
of the various growth factors.
Their clinical application in skeletal muscle injuries
should be optimized and even combined with new tech-
niques such as gene therapy and tissue engineering, not
merely based on experimental studies or empirical evidence.
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